Progenics Pharmaceuticals Inc

Find Ratings Reports
PGNX : NASDAQ : Health Care
$10.23 -0.12 | -1.16%
Today's Range: 10.17 - 10.49
Avg. Daily Volume: 1370500.0
03/29/17 - 4:00 PM ET

Financial Analysis


PROGENICS PHARMACEUTICAL INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the industry, the net income growth did not. PROGENICS PHARMACEUTICAL INC is extremely liquid. Currently, the Quick Ratio is 8.79 which clearly shows the ability to cover any short-term cash needs. PGNX managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

During the same period, stockholders' equity ("net worth") has increased by 15.81% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)4.655.1
EBITDA ($mil)-10.45-6.05
EBIT ($mil)-10.67-6.22
Net Income ($mil)-7.2-7.15


Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)138.9174.1
Total Assets ($mil)198.99131.25
Total Debt ($mil)49.450.0
Equity ($mil)104.7690.46


Profitability Q4 FY16 Q4 FY15
Gross Profit Margin-224.72-118.7
EBITDA Margin-224.72-118.7
Operating Margin-229.41-121.98
Sales Turnover0.350.07
Return on Assets5.43-29.79
Return on Equity10.31-43.23
Debt Q4 FY16 Q4 FY15
Current Ratio9.058.56
Debt/Capital0.320.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)70.1969.95
Div / share0.00.0
EPS-0.1-0.1
Book value / share1.491.29
Institutional Own % n/a n/a
Avg Daily Volume1319299.01338006.0

Valuation


HOLD. PROGENICS PHARMACEUTICAL INC's P/E ratio indicates a significant premium compared to an average of 38.87 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 26.33. To use another comparison, its price-to-book ratio of 7.43 indicates a significant premium versus the S&P 500 average of 2.93 and a significant discount versus the industry average of 11.85. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
PGNX 69.31 Peers 38.87   PGNX 40.52 Peers 22.28

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

PGNX is trading at a significant premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

PGNX is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
PGNX 33.61 Peers 58.77   PGNX NM Peers 0.49

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

PGNX's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

PGNX's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
PGNX 7.43 Peers 11.85   PGNX 128.57 Peers 165.61

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

PGNX is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, PGNX is expected to trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
PGNX 11.21 Peers 256.31   PGNX 700.24 Peers 609.16

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

PGNX is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

PGNX has a sales growth rate that exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades